Changes of serofast status in HIV negative asymptomatic neurosyphilis patients after treatment

Jing Liu, Tianwei Zhao, Chun Zhou, Huiwen Yan, Wenhui LunFrontiers in Medicine 2022 · DOI

Abstract

Serofast status—the persistence of non-treponemal antibody titers despite standard therapy—remains a significant challenge in syphilis management. This study investigated whether asymptomatic neurosyphilis (ANS) contributes to this state and if targeted anti-neurosyphilis treatment can resolve it. While patients treated for ANS showed significantly higher serological cure rates compared to a control group, nearly 70% remained serofast after one year, suggesting that the condition may involve complex immunological factors beyond active infection.

Introduction

Syphilis treatment is generally straightforward, yet 15–20% of patients enter a "serofast" state where Rapid Plasma Reagin (RPR) titers fail to decline significantly. This raises a critical clinical question: is the persistent titer an "immunological scar" or a sign of a hidden central nervous system (CNS) infection? If the latter, these patients have Asymptomatic Neurosyphilis (ANS) and require intensive treatment. This study evaluates the impact of anti-neurosyphilis therapy on serological outcomes in these patients.

Methodology

Researchers at Beijing Ditan Hospital conducted a retrospective cohort study of 445 HIV-negative, serofast syphilis patients. Participants were divided based on cerebrospinal fluid (CSF) analysis:

  • ANS Group (n=136): Patients with abnormal CSF markers (elevated white blood cells or protein) but no neurological symptoms. This group received high-dose intravenous penicillin G for 14 days, followed by three weeks of intramuscular benzathine penicillin G.
  • Serofast Control Group (n=309): Patients with normal CSF who were monitored without additional treatment.

Both groups were followed every three months for one year. A "serological cure" was defined as a four-fold or greater drop in RPR titer or a negative result.

Key Findings

The study demonstrated that treating underlying ANS significantly improves the likelihood of achieving a serological cure. The cumulative cure rates for the ANS group were consistently higher than the control group at all intervals: 9.6% vs. 4.2% at 3 months, 22.1% vs. 12.6% at 6 months, and reaching 30.2% vs. 20.1% at 12 months.

Kaplan–Meier plots showing the percentage of patients remaining in serofast status over 12 months for the ANS and control groups.

Despite the statistical benefit of treatment, the majority of patients (69.8% in the ANS group) remained serofast at the end of the year. This indicates that while CNS infection is a factor for some, it does not fully explain the serofast phenomenon for most patients.

Analysis of Biomarkers

The researchers also investigated whether specific CSF markers, such as the Fluorescent Treponemal Antibody-Absorption (FTA-ABS) test, could predict treatment success. Interestingly, the presence of CSF FTA-ABS IgG did not significantly correlate with higher serological cure rates, highlighting the difficulty of using single biomarkers to predict clinical outcomes.

Comparison of serological cure rates in the ANS group based on CSF FTA-ABS IgG status, showing no significant difference between groups.

Discussion and Conclusion

The findings suggest a "golden window" for treatment response, with the most significant divergence in cure rates occurring within the first six months post-therapy. The persistence of serofast status in nearly 70% of treated ANS patients suggests that the condition may be driven by long-term host-pathogen interactions or immune system alterations rather than just persistent active infection.

Clinically, these results support screening serofast patients for ANS, as targeted treatment offers a better chance of serological resolution. However, the high rate of persistent serofast status highlights the need for further research into the molecular pathogenesis of this condition to develop more effective management strategies.

Summary updated

Abstract

Serofast status after therapy in syphilis patients is a common phenomenon. A proportion of patients who have serofast status exhibit abnormal cerebrospinal fluid test results, which can be defined as asymptomatic neurosyphilis (ANS); however, it remains unclear whether ANS patients can achieve serological cure after anti-neurosyphilis treatment as quickly as other serofast patients. In this study, non-treponemal pallidum antibody serological responses were studied in ANS and serofast control patients, and the cumulative rates of serological cure in the ANS group were 9.6, 22.1, 25.9, and 30.2% in 3, 6, 9, and 12 month after treatment, which were statistically higher than those of the serofast control group. The change gap in serological cure rates was even more pronounced within 6 months after treatment, but the majority of ANS patients had no change in serofast status at 12 months after treatment. Our study indicates that anti-neurosyphilis therapy can partially change the serofast status. As serofast status cannot easily be changed even under neurosyphilis treatment in the majority of patients, the pathogenesis of this condition needs further research.
BibTeX
@inproceedings{liu2022changes,
  author = {Jing Liu and Tianwei Zhao and Chun Zhou and Huiwen Yan and Wenhui Lun},
  title = {{Changes of serofast status in HIV negative asymptomatic neurosyphilis patients after treatment}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2022.938016},
}
Figure